화학공학소재연구정보센터
검색결과 : 72건
No. Article
1 Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
Yuan M, Liu HJ, Wu NIC, Wilson IA
Biochemical and Biophysical Research Communications, 538, 192, 2021
2 Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
Koenig PA, Das H, Liu HJ, Kummerer BM, Gohr FN, Jenster LM, Schiffelers LDJ, Tesfamariam YM, Uchima M, Wuerth JD, Gatterdam K, Ruetalo N, Christensen MH, Fandrey CI, Normann S, Todtmann JMP, Pritzl S, Hanke L, Boos J, Yuan M, Zhu XY, Schmid-Burgk JL, Kato H, Schindler M, Wilson IA, Geyer M, Ludwig KU, Hallberg BM, Wu NC, Schmidt FI
Science, 371(6530), 691, 2021
3 Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Rogers TF, Zhao FZ, Huang DL, Beutler N, Burns A, He WT, Limbo O, Smith C, Song G, Woehl J, Yang LL, Abbott RK, Callaghan S, Garcia E, Hurtado J, Parren M, Peng LH, Ramirez S, Ricketts J, Ricciardi MJ, Rawlings SA, Wu NC, Yuan M, Smith DM, Nemazee D, Teijaro JR, Voss JE, Wilson IA, Andrabi R, Briney B, Landais E, Sok D, Jardine JG, Burton DR
Science, 369(6506), 956, 2020
4 Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses
Wu NC, Thompson AJ, Lee JM, Su W, Arlian BM, Xie J, Lerner RA, Yen HL, Bloom JD, Wilson IA
Science, 368(6497), 1335, 2020
5 A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
Yuan M, Wu NC, Zhu XY, Lee CCD, So RTY, Lv HB, Mok CKP, Wilson IA
Science, 368(6491), 630, 2020
6 Structural basis of a shared antibody response to SARS-CoV-2
Yuan M, Liu HJ, Wu NC, Lee CCD, Zhu XY, Zhao FZ, Huang DL, Yu WL, Hua YZ, Tien H, Rogers TF, Landais E, Sok D, Jardine JG, Burton DR, Wilson IA
Science, 369(6507), 1119, 2020
7 A small-molecule fusion inhibitor of influenza virus is orally active in mice
van Dongen MJP, Kadam RU, Juraszek J, Lawson E, Brandenburg B, Schmitz F, Schepens WBG, Stoops B, van Diepen HA, Jongeneelen M, Tang C, Vermond J, Real AVO, Blokland S, Garg D, Yu WL, Goutier W, Lanckacker E, Klap JM, Peeters DCG, Wu J, Buyck C, Jonckers THM, Roymans D, Roevens P, Vogels R, Koudstaal W, Friesen RHE, Raboisson P, Dhanak D, Goudsmit J, Wilson IA
Science, 363(6431), 1056, 2019
8 Broadly protective human antibodies that target the active site of influenza virus neuraminidase
Stadlbauer D, Zhu XY, McMahon M, Turner JS, Wohlbold TJ, Schmitz AJ, Strohmeier S, Yu WL, Nachbagauer R, Mudd PA, Wilson IA, Ellebedy AH, Krammer F
Science, 366(6464), 499, 2019
9 A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses
Steichen JM, Lin YC, Havenar-Daughton C, Pecetta S, Ozorowski G, Willis JR, Toy L, Sok D, Liguori A, Kratochvil S, Torres JL, Kalyuzhniy O, Melzi E, Kulp DW, Raemisch S, Hu XZ, Bernard SM, Georgeson E, Phelps N, Adachi Y, Kubitz M, Landais E, Umotoy J, Robinson A, Briney B, Wilson IA, Burton DR, Ward AB, Crotty S, Batista FD, Schief WR
Science, 366(6470), 1216, 2019
10 cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate
Dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens AJ, Go EP, Ketas TJ, Yasmeen A, Klasse PJ, Sayeed E, Desaire H, Crispin M, Wilson IA, Sanders RW, Hassell T, Ward AB, Moore JP
Biotechnology and Bioengineering, 115(4), 885, 2018